A recent study found that cells with the M-MDSCs phenotype CD14+HLA-DR−/low are present at significantly higher frequencies in early-stage BC patients (40 patients with clinical stages I/II), suggesting that M-MDSCs mostly participate to the development of BC by protecting tumor cells from immune attack. The gene discussed is CD14; the disease is neoplasm.